BIENAIME JEAN JACQUES sold $204K of IMNM
BIENAIME JEAN JACQUES sold 10,500 shares of Immunome Inc. (IMNM) at an average of $19.41 ($19.41–$19.44, $0.20M total) across 2 trades on 2026-06-05.
How this was made
The 30-second read
Why it matters
The newest information is the director’s open-market sale of 10,500 shares at ~$19.41, which may slightly pressure sentiment but does not constitute company-specific operational news.
Market read
A fresh insider-sale datapoint for IMNM; useful for sentiment/positioning but unlikely to drive fundamentals by itself.
What to watch
The filing doesn’t disclose intent, future plans, or whether other insiders/large holders acted; traders should avoid over-weighting one director sale without corroborating fundamentals.
Background
The article is an SEC Form 4 insider transaction disclosure for Immunome Inc. (IMNM).
Ticker impact
Immunome director Bienaime Jean Jacques sold 10,500 shares in open-market transactions at ~$19.41, per a fresh SEC Form 4 filed June 9.
Likely limited near-term impact; any effect should be small unless accompanied by other negative company catalysts.
The filing is primary-source and time-stamped, but the article provides only the sale details (no accompanying company news, guidance, or enforcement action).
Market effects
No sector read-through; this is a single-company insider transaction with no stated operational or regulatory change.
None indicated.
None indicated.
Counterpoint
Because the sale was not under a pre-arranged 10b5-1 plan, it could be driven by personal liquidity/tax needs rather than a bearish view on the pipeline.
Key entities
- issuerImmunome Inc.
Subject of the SEC Form 4 insider sale disclosure (IMNM).
- insiderBIENAIME JEAN JACQUES
Director who sold 10,500 shares in open-market transactions on June 5; holdings after sale: 32,915 shares.